Internal Medicine, Pulmonary Disease · Lubbock, TX
NPI
1205838653
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
3621 22nd St, Suite 400
Lubbock, TX, 79410
Phone (806) 791-8484
Groups this clinician bills Medicare through
Medicare paid, 2024
$98K
1,915 services
Medicare patients, 2024
385
Average age 76
Drug cost, 2024
$2.4M
2,647 prescriptions
Company payments, 2025
$1,130
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark W Johnson was code 99214 (office e&m - established), 352 times for 252 patients. In total Mark W Johnson billed 1,915 services in 32 codes, and Medicare paid $98K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-10-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 352 | 252 | $67.63 | $24K |
| 99233 Hospital E&M - Subsequent | Facility | 293 | 65 | $89.71 | $26K |
| 99232 Hospital E&M - Subsequent | Facility | 178 | 61 | $59.80 | $11K |
| 94010 Pulmonary Function Testing | Facility | 118 | 109 | $5.42 | $640 |
| 94729 Pulmonary Function Testing | Facility | 103 | 97 | $5.93 | $610 |
| 71045 X-ray - Chest | Facility | 103 | 87 | $5.97 | $615 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 92 | 86 | $12.55 | $1,155 |
| 71250 CT/CTA - Chest | Office | 70 | 61 | $57.39 | $4,017 |
| 99215 Office E&M - Established | Facility | 60 | 43 | $101.69 | $6,101 |
| 71046 X-ray - Chest | Facility | 52 | 48 | $6.85 | $356 |
| 99291 Critical Care E&M | Facility | 49 | 19 | $160.99 | $7,889 |
| 99223 Hospital E&M - Initial | Facility | 48 | 43 | $131.40 | $6,307 |
| 99213 Office E&M - Established | Facility | 44 | 43 | $46.66 | $2,053 |
| 94060 Pulmonary Function Testing | Facility | 38 | 35 | $7.10 | $270 |
| 94727 Pulmonary Function Testing | Facility | 34 | 34 | $7.40 | $252 |
By year: 2022 $115K for 2,111 services; 2023 $143K for 2,213 services; 2024 $98K for 1,915 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark W Johnson prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 511 prescriptions and refills. In total Mark W Johnson wrote 2,647 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 511 | 669 | 93 | $417K |
| Prednisone Generic | 335 | 379 | 120 | $1,463 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 280 | 372 | 74 | $8,559 |
| Montelukast Sodium Generic | 191 | 372 | 44 | $1,441 |
| Doxycycline Hyclate Generic | 169 | 169 | 90 | $1,251 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 114 | 136 | 26 | $83K |
| Spiriva Respimat Tiotropium Bromide | 104 | 136 | 21 | $69K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 92 | 107 | 12 | $47K |
| Breo Ellipta Fluticasone/Vilanterol | 65 | 73 | Under 11 | $28K |
| Symbicort Budesonide/Formoterol Fumarate | 62 | 88 | 19 | $20K |
| Ofev Nintedanib Esylate | 54 | 55 | Under 11 | $675K |
| Pirfenidone Generic | 52 | 54 | Under 11 | $278K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 47 | 56 | 11 | $228 |
| Azithromycin Generic | 42 | 44 | 32 | $244 |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 36 | 40 | Under 11 | $20K |
Brand drugs: 1,371 claims; generic drugs: 1,276 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark W Johnson $1,130 ($1,130 in general payments such as food, travel and fees) from 13 companies. The largest payer was GlaxoSmithKline, LLC. with $419.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 24 | $419 |
| Grifols USA, LLC | 7 | $148 |
| Electromed, Inc. ELMD | 6 | $109 |
| Amgen Inc. AMGN | 6 | $103 |
| Verona Pharma, Inc. VRNA | 4 | $102 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $60.59 |
| Pfizer Inc. PFE | 3 | $59.03 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $31.06 |
| Viatris Specialty LLC | 2 | $29.19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.